Time-Restricted Eating Didn't Change IGF-1, But Bigger Weight Loss Did Shift Cancer-Linked Biomarkers: What the Research Shows

Time-Restricted Eating Didn't Change IGF-1, But Bigger Weight Loss Did Shift Cancer-Linked Biomarkers: What the Research Shows

Medical disclaimer: This article summarises published research for informational purposes only. It is not medical advice and is not a substitute for guidance from a qualified health professional. Always consult your doctor before starting any fasting protocol, especially if you have an existing health condition or take medication.

Study at a Glance

What This Study Looked At

Obesity is linked to disrupted levels of IGF-1 (insulin-like growth factor 1) and its binding proteins — a hormone pathway implicated not just in growth and aging, but in cardiovascular disease, diabetes, and cancer risk, including colorectal cancer-related pathways. Researchers at the University of Illinois Chicago set out to answer a specific question: does time-restricted eating (TRE) change this cancer-relevant hormone axis in adults with obesity, and if so, is that change driven by the eating pattern itself or by the weight loss it produces? This adds a useful data point to the broader picture of how intermittent fasting affects inflammation and metabolic risk markers.

Who Was Studied

Participant profile: Adults with obesity enrolled in an 8-week trial conducted at the University of Illinois Chicago. This analysis pooled the 4-hour and 6-hour TRE arms together to compare against the control group.

How TRE worked in this study: Participants in the intervention arms confined all daily calorie intake to either a 4-hour or 6-hour window, with no other specific calorie counting or macronutrient targets prescribed. Outside the eating window, participants consumed only water and non-caloric beverages.

What the Researchers Found

IGF-1 and Its Binding Proteins

• Across the full TRE group, IGF-1 and two of its three measured binding proteins did not shift compared to control — TRE alone, without more substantial weight loss, wasn't enough to move this hormone axis.
• The key finding was that IGFBP2 rose significantly only in the subgroup of participants who lost more than 3.5% of their baseline body weight, suggesting the benefit is tied to the amount of weight lost, not the eating pattern by itself.

Metabolic and Oxidative Stress Markers

• Insulin levels improved with TRE.
• HOMA-IR (a marker of insulin resistance) improved with TRE.
• 8-isoprostane, a marker of oxidative stress, decreased significantly in the higher-weight-loss subgroup.
• Leptin, the hormone that signals fullness and is often elevated in obesity, decreased significantly in the higher-weight-loss subgroup.

What Did Not Change

• IGF-1 itself showed no significant change in either the full TRE group or the higher-weight-loss subgroup.
• IGFBP1 and IGFBP3 remained unchanged across all groups.

What the Researchers Concluded

The authors concluded that 8 weeks of daily time-restricted eating did not meaningfully alter circulating IGF-1 in adults with obesity, but that achieving greater weight loss within that window (above roughly 3.5% of baseline body weight) was associated with favorable shifts in IGFBP2, leptin, and oxidative stress markers — suggesting these particular benefits depend on how much weight is actually lost, rather than being an automatic effect of restricting the eating window.

What This Means If You Fast

• TRE alone isn't a guaranteed hormone reset. If your goal includes shifting cancer-relevant biomarkers like IGFBP2, the amount of weight you lose during a TRE protocol appears to matter more than simply adopting the eating window.
• A 3.5%+ weight loss threshold showed up as meaningful in this study. For an adult starting around 90kg (200 lbs), that's roughly 3kg (7 lbs) — a realistic target within an 8-week window for many people following a consistent TRE schedule.
• Insulin and insulin resistance improved regardless of weight-loss magnitude, which lines up with a large body of other TRE and insulin sensitivity research — this is one of the more consistent benefits of time-restricted eating even before major weight loss occurs.
• Oxidative stress reduction tracked with weight loss, not just the fasting window itself, reinforcing that the metabolic gains from TRE compound as adherence and results build over time.
• This was an exploratory, secondary analysis, not the trial's primary outcome — treat the specific numbers as suggestive rather than definitive, and expect follow-up studies to test these relationships directly.

Study Limitations

• Small sample size (n=49 total, with the higher-weight-loss subgroup analysis based on an even smaller number of participants), which limits statistical power and the precision of subgroup findings.
• This was an exploratory, secondary analysis of biomarkers from a trial that was not originally designed to test IGF-1/IGFBP outcomes as its primary endpoint.
• Short duration (8 weeks) — longer-term studies are needed to know whether these biomarker shifts persist or grow with sustained TRE.
• The study combined 4-hour and 6-hour TRE arms into a single "TRE" group, which may obscure differences between the two windows.
• Full numerical results (exact percentage changes and p-values for each marker) could not be independently re-verified from the primary source at the time of writing due to database access restrictions; figures above reflect the best available published summary data.

Source

Ali, M., et al. (2024). Effect of Time-Restricted Eating on Circulating Levels of IGF1 and Its Binding Proteins in Obesity: An Exploratory Analysis of a Randomized Controlled Trial. Nutrients, 16(20), 3476. PMID: 39458471

Frequently Asked Questions

Does intermittent fasting lower IGF-1 levels?

In this particular 8-week time-restricted eating study, IGF-1 itself did not change significantly compared to control, even though other markers like insulin and insulin resistance did improve. Other fasting studies using longer or more calorie-restrictive protocols, such as fasting-mimicking diets, have shown larger IGF-1 reductions.

What is IGFBP2 and why does it matter for cancer risk?

IGFBP2 is a protein that binds and regulates IGF-1 activity in the bloodstream. Along with related markers in the IGF axis, it's studied as part of the biological pathway linking obesity to increased risk of several cancers, including colorectal cancer, because it influences how much "free" IGF-1 is available to stimulate cell growth.

How much weight do I need to lose for time-restricted eating to shift these markers?

In this study, favorable changes in IGFBP2, leptin, and oxidative stress markers only showed up in participants who lost more than 3.5% of their starting body weight over the 8-week period — a threshold worth keeping in mind if biomarker improvement, not just the eating window itself, is your goal.

Is a 4-hour or 6-hour eating window better for these outcomes?

This study did not separately report outcomes for the 4-hour versus 6-hour groups; both were pooled together for the biomarker analysis, so it isn't possible to say from this study alone whether a shorter window produces different hormonal effects than a longer one.

Does time-restricted eating improve insulin resistance even without much weight loss?

Yes — in this study, insulin and HOMA-IR (a measure of insulin resistance) improved in the TRE group overall, independent of how much weight participants lost, suggesting this particular benefit shows up earlier than changes in the IGF-1/IGFBP axis.

Related Research and Articles

• Time-Restricted Eating Preserves Lean Mass During Weight Loss
• Intermittent Fasting and Insulin Resistance in Women
• Intermittent Fasting and Inflammation: What Women Should Know
• Alternate Day Fasting and LDL Particle Size
• Intermittent Fasting and Breast Cancer Recurrence Risk
• Fasting for Weight Loss: Why It's Not Just About Calories

Want the complete guide to fasting? Get Intermittent Fasting in Practice on Amazon — and claim 3 months free on our fasting app at fastinginpractice.com/redeem.